Ultragenyx Pharmaceutical Inc. (RARE) insider have most recently took part in a trading activity. On Aug 28, 2017 Kakkis Emil D, President & CEO bought 7,500 shares having total worth of $393,900 at the price of $52.52 per share, following the transaction a total of 2,990,310 shares owned by Kakkis Emil D.
Furthermore, over the past 12 months , the stock was traded 10 times by insiders. In 10 of these trades, the insider was a seller .
Shares of Ultragenyx Pharmaceutical Inc. (RARE) traded up 3.11% on Aug 28, 2017, hitting $53. 326,942 shares of the company’s stock traded hands. Ultragenyx Pharmaceutical Inc. has a 52 week low of $47.26 and a 52 week high of $88.8. The company’s market cap is $2,870 million.
Ultragenyx Pharmaceutical Inc. (RARE) last announced its earnings results on Jul 27, 2017. The company reported -1.72 earnings per share (EPS) for the quarter, higher than the consensus estimate of -1.73 by $0.01., compared to the consensus estimate of $0 million. During the same quarter in the previous year, the company posted -1.46 earnings per share. The company’s revenue for the quarter was down 100% on a year-over-year basis.
|earnings per share||-1.72||-1.63||-1.75||-1.64||-1.46||-1.35||-1.42||-1.03||-0.83||-0.63|
Ultragenyx Pharmaceutical Inc. has been the subject of a number of recent research reports. Analysts at Wedbush Reiterates shares of Ultragenyx Pharmaceutical Inc. to an Outperform rating in a research note. They now have a $80.00 price target on the stock.
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018